<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">2526</journal-id><journal-id journal-id-type="pmc-domain">cardther</journal-id><journal-title-group><journal-title>Cardiology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8261</issn><issn pub-type="epub">2193-6544</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11607373</article-id><article-id pub-id-type="pmcid-ver">PMC11607373.1</article-id><article-id pub-id-type="pmcaid">11607373</article-id><article-id pub-id-type="pmcaiid">11607373</article-id><article-id pub-id-type="pmid">39368027</article-id><article-id pub-id-type="doi">10.1007/s40119-024-00385-2</article-id><article-id pub-id-type="publisher-id">385</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>National Trends in Aspirin Use and Expenditures in the United States: Analysis of The Medical Expenditure Panel Survey 2000&#8211;2021</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0457-5851</contrib-id><name name-style="western"><surname>Thyagaturu</surname><given-names initials="H">Harshith</given-names></name><address><email>harshith.thyagaturu@hsc.wvu.edu</email><email>harshihbk@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="S">Shafaqat</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seetharam</surname><given-names initials="K">Karthik</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Upreti</surname><given-names initials="P">Prakash</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doddi</surname><given-names initials="A">Akshith</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atti</surname><given-names initials="L">Lalitsiri</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roma</surname><given-names initials="N">Nicholas</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lacoste</surname><given-names initials="JL">Jordan L.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Angirekula</surname><given-names initials="A">Aakash</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salami</surname><given-names initials="J">Joseph</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nasir</surname><given-names initials="K">Khurram</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balla</surname><given-names initials="S">Sudarshan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011vxgd24</institution-id><institution-id institution-id-type="GRID">grid.268154.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6140</institution-id><institution>Department of Cardiology, </institution><institution>West Virginia University School of Medicine, </institution></institution-wrap>1 Medical Center Dr, Morgantown, WV 26506 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05ect4e57</institution-id><institution-id institution-id-type="GRID">grid.64337.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 0662 7451</institution-id><institution>Department of Internal Medicine, </institution><institution>Louisiana State University, </institution></institution-wrap>Shreveport, LA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00yzb1d91</institution-id><institution-id institution-id-type="GRID">grid.417280.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0381 3533</institution-id><institution>Department of Internal Medicine, </institution><institution>Wyckoff Heights Medical Center, </institution></institution-wrap>Brooklyn, NY USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00yfpz909</institution-id><institution-id institution-id-type="GRID">grid.417055.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0382 5614</institution-id><institution>Sands-Constellation Heart Institute, </institution><institution>Rochester Regional Health, </institution></institution-wrap>Rochester, NY USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/018dx8725</institution-id><institution-id institution-id-type="GRID">grid.416223.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0450 5161</institution-id><institution>Department of Internal Medicine, </institution><institution>Sparrow Hospital-Michigan State University, </institution></institution-wrap>Lansing, MI USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qfnkv67</institution-id><institution-id institution-id-type="GRID">grid.416974.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0435 9774</institution-id><institution>Department of Internal Medicine, </institution><institution>St Luke&#8217;s Hospitals, </institution></institution-wrap>Bethlehem, PA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fbnx371</institution-id><institution-id institution-id-type="GRID">grid.412950.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0455 5644</institution-id><institution>Department of Pharmacy, </institution><institution>WVU Medicine, </institution></institution-wrap>Morgantown, WV USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hj54h04</institution-id><institution-id institution-id-type="GRID">grid.89336.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9924</institution-id><institution>Undergraduate Researcher, </institution><institution>University of Texas at Austin, </institution></institution-wrap>Austin, TX USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p8w6387</institution-id><institution-id institution-id-type="GRID">grid.255951.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0377 5792</institution-id><institution>Department of Internal Medicine, Charles E. Schmidt College of Medicine, </institution><institution>Florida Atlantic University, </institution></institution-wrap>Boca Raton, FL USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/027zt9171</institution-id><institution-id institution-id-type="GRID">grid.63368.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 0445 0041</institution-id><institution>Department of Cardiology, </institution><institution>Houston Methodist Hospital, </institution></institution-wrap>Houston, TX USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><volume>13</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">476072</issue-id><fpage>679</fpage><lpage>694</lpage><history><date date-type="received"><day>29</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-01 00:25:14.133"><day>01</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40119_2024_Article_385.pdf"/><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Since its invention in 1897, aspirin (ASA) has been the most widely used and cost-effective antiplatelet agent to prevent and treat atherosclerotic cardiovascular disease (ASCVD). We aimed to study the trends and expenditures associated with ASA use in the USA.</p></sec><sec><title>Methods</title><p id="Par2">We conducted a serial cross-sectional analysis using the Medical Expenditure Panel Survey data from January 2000 to December 2021, focusing on adults aged&#8201;&#8805;&#8201;40&#160;years. Total and out-of-pocket expenditures associated with ASA were estimated to 2021 US dollars (USD). Trends, demographics, and predictors of ASA use among patients with and without ASCVD were also evaluated.</p></sec><sec><title>Results</title><p id="Par3">A total of 53&#160;million adults were identified during the study period. The number of ASA users increased from 2.9&#160;million to 6.6&#160;million with increased female (36.7%&#8211;49.7%; <italic toggle="yes">p</italic>&#160;trend&#8201;=&#8201;0.02) and African American (13%&#8211;18.9%; <italic toggle="yes">p</italic>&#160;trend&#8201;=&#8201;0.03) representation amongst all ASA users during the survey period. The use of low-dose ASA increased, while high-dose ASA declined significantly. Only 50% of all ASA users had known ASCVD. The most prevalent ASA users among patients with ASCVD were those aged&#8201;&#8805;&#8201;70&#160;years, while patients without ASCVD, it was the 50&#8211;69 age group. The total annual expenditure on ASA averaged approximately 60&#160;million USD, with 27.3&#160;million USD out-of-pocket.</p></sec><sec><title>Conclusion</title><p id="Par4">Total and low-dose (81&#160;mg) ASA use has increased, while high-dose (325&#160;mg) ASA has declined. ASA use for primary prevention has risen among adults aged 50&#8211;69&#160;years, and patients&#8201;&#8805;&#8201;70&#160;years continue to use ASA without known ASCVD. Further studies are needed to understand the implications of increased ASA use, especially among those without ASCVD.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40119-024-00385-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Aspirin</kwd><kwd>Atherosclerotic cardiovascular disease</kwd><kwd>Medical Expenditure Panel Survey</kwd><kwd>Myocardial infarction</kwd><kwd>Coronary artery disease</kwd><kwd>Atherosclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Healthcare Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e340"><title>Key Summary Points</title><p>
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">Why carry out this study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin (ASA) is commonly used for atherosclerotic cardiovascular disease (ASCVD) prevention, but trends in its use across demographic groups and dosages remain insufficiently explored.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">What was learned from the study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">ASA use significantly increased, with more low-dose use and less high-dose use, rising from 2.9&#160;million to 6.6&#160;million users, particularly among women and African Americans.</td></tr><tr><td align="left" colspan="1" rowspan="1">Despite guidelines advising against ASA for primary prevention in older adults without ASCVD, many patients aged&#8201;&#8805;&#8201;70&#160;years continue its use, highlighting the need for better education on guideline adherence.</td></tr><tr><td align="left" colspan="1" rowspan="1">The study emphasizes the importance of ongoing monitoring and education on ASA use, particularly among older adults without ASCVD, to improve outcomes and minimize risks.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec2" sec-type="introduction"><title>Introduction</title><p id="Par6">Atherosclerotic cardiovascular diseases (ASCVDs) are the leading cause of morbidity and mortality in the USA, with an estimated 800,000 Americans suffering a myocardial infarction (MI) event annually [<xref ref-type="bibr" rid="CR1">1</xref>]. The burden accounts for one in four deaths in the USA, incurring an annual burden of $200&#160;billion on the healthcare system [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Poorly controlled atherosclerotic risk factors and suboptimal use of preventive therapies continue to be prevalent in those with and without atherosclerotic heart disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Historically, multiple societal guidelines have recommended aspirin (ASA) use for primary and secondary prevention of ASCVD [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. The US Preventive Services Task Force (USPSTF) recommends low-dose ASA for primary prevention of cardiovascular disease (CVD) in adults aged 40 to 59&#160;years with a 10% or greater 10-year CVD risk, while advising against its use for primary CVD prevention in adults aged 60&#160;years or older [<xref ref-type="bibr" rid="CR7">7</xref>]. However, recent studies have raised concerns about the risks of bleeding with ASA use in specific high-risk patient populations, which can outweigh the cardiovascular risk reduction [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The 2019 ACC/AHA (American College of Cardiology/American Heart Association) guidelines [<xref ref-type="bibr" rid="CR10">10</xref>]. The ASPREE trial (Aspirin in Reducing Events in the Elderly) found that ASA use in healthy older adults did not prolong disability-free survival and was associated with a significant risk of major hemorrhage [<xref ref-type="bibr" rid="CR9">9</xref>]. Similarly, the ARRIVE trial (Aspirin to Reduce Risk of Initial Vascular Events) showed that ASA did not significantly reduce the risk of major cardiovascular events in patients at moderate risk, but increased the risk of gastrointestinal bleeding [<xref ref-type="bibr" rid="CR11">11</xref>]. The ASCEND trial (A Study of Cardiovascular Events in Diabetes) indicated that while ASA reduced the risk of serious vascular events in patients with diabetes, it also increased the risk of major bleeding [<xref ref-type="bibr" rid="CR8">8</xref>]. As a result, there has been an overall shift toward an individualized approach to ASA use for the primary prevention of ASCVD. However, the ideal ASA dose was a topic of clinical debate until recently. The Adaptable trial randomized 15,000 patients to high- vs. low-dose ASA and showed no difference in cardiovascular outcomes between the two doses [<xref ref-type="bibr" rid="CR11">11</xref>]. Interestingly, in 2014, the National Cardiovascular Data Registry (NCDR) showed that more than 60% of acute MI survivors were discharged on a high dose of ASA, and after that, it continued indefinitely in most of these patients [<xref ref-type="bibr" rid="CR12">12</xref>]. In the context of evolving guidelines and recent data, the trends of ASA utilization among the US adult population remain underexplored. Therefore, we performed a 22-year retrospective cohort study of US adults 40&#160;years or older by utilizing the 2000&#8211;2021 Medical Expenditure Panel Survey (MEPS) database to determine the overall pattern and changes in the prevalence of ASA use over time. Our goal is to analyze the overall trend and expenditures of ASA use (both 81&#160;mg and 325&#160;mg) in the USA, considering newer guidelines. Additionally, we aim to examine the prevalence of ASA use across different races, income categories, and age groups. This comprehensive approach will provide a clearer understanding of the current landscape of ASA use and its alignment with recent recommendations.</p></sec><sec id="Sec3" sec-type="materials|methods"><title>Methods</title><sec id="Sec4"><title>Study Design and Population</title><p id="Par7">We performed a 22-year retrospective longitudinal cohort study of US adults 40&#160;years or older using the January 2000 to December 2021 MEPS database. The Agency for Healthcare Research and Quality sponsors the MEPS, and it is a nationally representative large-scale survey of noninstitutionalized US civilians, their employers, and medical providers, including pharmacies. It collects data on the specific health services, how frequently they are used, the cost of these services, how they are paid for, and the scope, breadth, and cost of health insurance use. The MEPS currently has three major components: the Household Component (MEPS-HC), the Insurance Component, and the Medical Provider Component (MPC). The MEPS-HC collects data from a sample of families and individuals in selected communities across the USA, drawn from a nationally representative subsample that participated in the previous year&#8217;s National Health Interview Survey conducted by the National Center for Health Statistics. Patients in nursing homes or assisted living facilities were excluded from the survey. Each surveyed household was interviewed over the telephone five times (rounds) over 2&#160;years, providing current and continuous estimates of healthcare expenditures at both the person and household levels. Medical conditions, including ASCVD stratification, were based on the International Statistical Classification of Diseases, Ninth (ICD-9), and Tenth (ICD-10) Revision, Clinical Modification (CM) diagnosis (see Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S1</xref>), or self-reported history of diagnosis. The participants with known ASCVD included those with (1) coronary artery disease (CAD) and (2) stroke and/or peripheral arterial disease. This study used publicly available de-identified data from the MEPS website [<xref ref-type="bibr" rid="CR13">13</xref>]. Hence, ethical approval was not obtained.</p></sec><sec id="Sec5"><title>Aspirin Use and Expenditure</title><p id="Par8">During the interview, the respondents were asked to supply the name of any prescribed medicine they or family members purchased or otherwise obtained during that round. Over-the-counter purchases were also included since the responses were entered verbatim. With written permission from participants, pharmacies were contacted to obtain a computer-generated profile on the medication name, national drug code, dose, quantity, amount paid, and source of payment for each prescription. In this study, the ASA use was categorized into low-dose (81&#160;mg) and high-dose (325&#160;mg). The total dollar amount paid and out-of-pocket (OOP) expenditure were reported for each drug. Expenditures were adjusted to 2021 US dollars using the Consumer Price Index calculator provided by the US Bureau of Labor Statistics. Missing data were handled by utilizing the MEPS Pharmacy Component (PC) data to impute information collected from pharmacy providers.</p></sec><sec id="Sec6"><title>Covariates</title><p id="Par9">MEPS-HC files provide information about the demographic characteristics of each person. Extracted elements include age, sex, region, race/ethnicity, family income, insurance coverage, and comorbidities. Age categories were defined as 40&#8211;49, 50&#8211;69, and &#8805;&#8201;70&#160;years. Regions were categorized as Northeast, Midwest, South, and West. Race/ethnicity were divided into six categories: White, African American, Hispanic, Asian or Pacific Islander, Native American, and other (if multiple races were reported). Using the Federal Poverty Line (FPL) as the reference entity, five categories of family income were identified: poor/negative (&#8804;&#8201;100% of FPL), near poor (100&#8211;125% of FPL), low income (125&#8211;200% of FPL), middle income (200&#8211;400% of FPL), and high income (&#8805;&#8201;400% of the poverty line). We identified the comorbidities based on the appropriate ICD-9 and ICD-10-CM codes (see Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S1</xref>) reported in the medical conditions file, a subcomponent of the MEPS-MPC file.</p></sec><sec id="Sec7"><title>Statistical Analyses and Handling of Data Variables</title><p id="Par10">All statistical analyses were performed using Stata version 17.0-Standard Edition (SE) (StataCorp). Stata accounted for the complex survey sampling design of the MEPS using the available person-weights (person sampling units) and variance estimates (stratum) to calculate nationally representative totals, means, and rates. Data files including the full-year consolidated (FYC), medical condition (MC), and prescription medicine (PM) files were downloaded from the official MEPS website. We reshaped MC and PM files to create person-level data and merged with FYC to form annual files with medical conditions, medications, and expenditures. For ease of analysis and reporting, we pooled two consecutive calendar year annual files and adjusted the person-level weights accordingly. We applied the final person-weight adjusted for the 2-year cycles to the data. We used the svy: proportion and svy: tabulate commands to estimate the proportion of the population&#8217;s baseline characteristics. We also used the svy: mean command to estimate the average expenditure on ASA. For our trend analysis over the 20&#160;years, we used the append command to combine 20&#160;years of data and weighted logistic regression with the year as the predictor variable. Logistic regression models were used to identify predictors of ASA use, adjusting for potential confounders such as age, sex, race/ethnicity, region, and comorbidities. In all analyses, two-sided<italic toggle="yes"> p</italic>&#160;values less than 0.05 were considered statistically significant.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Demographic Shifts</title><p id="Par11">Our study included nearly 53&#160;million weighted US non-institutionalized adults from January 2000 to December 2021. The prevalence of ASA users increased from 2.9&#160;million in 2000&#8211;01 to 6.6&#160;million in 2018&#8211;19. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> describes the baseline characteristics of our study population by the pooled year groups. The mean age of ASA users remained unchanged throughout the study period (66.5&#8201;&#177;&#8201;12.1; <italic toggle="yes">p</italic>&#160;trend&#8201;=&#8201;0.37) whereas the representation of female patients using ASA increased across the study period (36.7% in 2001&#8211;02 vs. 49.7% in 2020&#8211;21; <italic toggle="yes">p</italic>&#160;trend&#8201;=&#8201;0.02). There was a steady increase in ASA use among African Americans (13% in 2000&#8211;01 to 18.9% in 2018&#8211;19; <italic toggle="yes">p</italic>&#160;trend&#8201;=&#8201;0.03), while a decline was noted among White patients (68.4% in 2000&#8211;01 to 52.9% in 2018&#8211;19; <italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01). Approximately 50% of our study population was in middle- or high-income groups. The representation of uninsured status amongst ASA users decreased across the study period (4.6% in 2000&#8211;01 to 0.7% in 2020&#8211;21; <italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01), while there was no statistically significant difference in the representation of public or private insurance.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline characteristics of the study population, Medical Expenditure Panel Survey database 2000&#8211;2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">2000&#8211;01</th><th align="left" colspan="1" rowspan="1">2002&#8211;03</th><th align="left" colspan="1" rowspan="1">2004&#8211;05</th><th align="left" colspan="1" rowspan="1">2006&#8211;07</th><th align="left" colspan="1" rowspan="1">2008&#8211;09</th><th align="left" colspan="1" rowspan="1">2010&#8211;11</th><th align="left" colspan="1" rowspan="1">2012&#8211;13</th><th align="left" colspan="1" rowspan="1">2014&#8211;15</th><th align="left" colspan="1" rowspan="1">2016&#8211;17</th><th align="left" colspan="1" rowspan="1">2018&#8211;19</th><th align="left" colspan="1" rowspan="1">2020&#8211;21</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>&#160;trend</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Total adults (&#8805;&#8201;40&#160;years) using ASA</td><td align="left" colspan="1" rowspan="1">2,991,123</td><td align="left" colspan="1" rowspan="1">3,053,127</td><td align="left" colspan="1" rowspan="1">3,656,287</td><td align="left" colspan="1" rowspan="1">3,002,881</td><td align="left" colspan="1" rowspan="1">3,891,969</td><td align="left" colspan="1" rowspan="1">4,360,832</td><td align="left" colspan="1" rowspan="1">6,272,478</td><td align="left" colspan="1" rowspan="1">7,103,557</td><td align="left" colspan="1" rowspan="1">6,656,978</td><td align="left" colspan="1" rowspan="1">6,640,820</td><td align="left" colspan="1" rowspan="1">5,789,527</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="13" rowspan="1">Age categories (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;40&#8211;49&#160;years</td><td align="left" colspan="1" rowspan="1">9.1</td><td align="left" colspan="1" rowspan="1">8.8</td><td align="left" colspan="1" rowspan="1">11.6</td><td align="left" colspan="1" rowspan="1">12.2</td><td align="left" colspan="1" rowspan="1">13.7</td><td align="left" colspan="1" rowspan="1">10.1</td><td align="left" colspan="1" rowspan="1">10.8</td><td align="left" colspan="1" rowspan="1">14.2</td><td align="left" colspan="1" rowspan="1">8.1</td><td align="left" colspan="1" rowspan="1">6.5</td><td align="left" colspan="1" rowspan="1">7.3</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;50&#8211;69&#160;years</td><td align="left" colspan="1" rowspan="1">48.7</td><td align="left" colspan="1" rowspan="1">45.6</td><td align="left" colspan="1" rowspan="1">50.5</td><td align="left" colspan="1" rowspan="1">43.6</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">56.4</td><td align="left" colspan="1" rowspan="1">51.8</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">53.5</td><td align="left" colspan="1" rowspan="1">55.1</td><td align="left" colspan="1" rowspan="1">49.7</td><td char="." align="char" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;70&#160;years</td><td align="left" colspan="1" rowspan="1">29.6</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">33.3</td><td align="left" colspan="1" rowspan="1">39.4</td><td align="left" colspan="1" rowspan="1">29.7</td><td align="left" colspan="1" rowspan="1">27.1</td><td align="left" colspan="1" rowspan="1">31.6</td><td align="left" colspan="1" rowspan="1">28.1</td><td align="left" colspan="1" rowspan="1">32.3</td><td align="left" colspan="1" rowspan="1">28.7</td><td align="left" colspan="1" rowspan="1">42.9</td><td char="." align="char" colspan="1" rowspan="1">0.38</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean age (years)</td><td align="left" colspan="1" rowspan="1">65.97</td><td align="left" colspan="1" rowspan="1">66.68</td><td align="left" colspan="1" rowspan="1">66.4</td><td align="left" colspan="1" rowspan="1">65.85</td><td align="left" colspan="1" rowspan="1">66.58</td><td align="left" colspan="1" rowspan="1">66.29</td><td align="left" colspan="1" rowspan="1">66.5</td><td align="left" colspan="1" rowspan="1">66.2</td><td align="left" colspan="1" rowspan="1">67.2</td><td align="left" colspan="1" rowspan="1">66.7</td><td align="left" colspan="1" rowspan="1">66.8</td><td char="." align="char" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Female (%)</td><td align="left" colspan="1" rowspan="1">36.7</td><td align="left" colspan="1" rowspan="1">40.5</td><td align="left" colspan="1" rowspan="1">46.5</td><td align="left" colspan="1" rowspan="1">48.5</td><td align="left" colspan="1" rowspan="1">49.3</td><td align="left" colspan="1" rowspan="1">46.2</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">49.8</td><td align="left" colspan="1" rowspan="1">48.2</td><td align="left" colspan="1" rowspan="1">47.1</td><td align="left" colspan="1" rowspan="1">49.7</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="13" rowspan="1">Regions (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Northeast</td><td align="left" colspan="1" rowspan="1">19.9</td><td align="left" colspan="1" rowspan="1">18.5</td><td align="left" colspan="1" rowspan="1">16.3</td><td align="left" colspan="1" rowspan="1">21.3</td><td align="left" colspan="1" rowspan="1">24.8</td><td align="left" colspan="1" rowspan="1">24.6</td><td align="left" colspan="1" rowspan="1">18.8</td><td align="left" colspan="1" rowspan="1">22.4</td><td align="left" colspan="1" rowspan="1">18.7</td><td align="left" colspan="1" rowspan="1">22.6</td><td align="left" colspan="1" rowspan="1">20.2</td><td char="." align="char" colspan="1" rowspan="1">0.43</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Midwest</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">23.3</td><td align="left" colspan="1" rowspan="1">20.7</td><td align="left" colspan="1" rowspan="1">19.6</td><td align="left" colspan="1" rowspan="1">16.4</td><td align="left" colspan="1" rowspan="1">14.6</td><td align="left" colspan="1" rowspan="1">18.2</td><td align="left" colspan="1" rowspan="1">17.9</td><td align="left" colspan="1" rowspan="1">19.1</td><td align="left" colspan="1" rowspan="1">22.8</td><td align="left" colspan="1" rowspan="1">23.7</td><td char="." align="char" colspan="1" rowspan="1">0.76</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;South</td><td align="left" colspan="1" rowspan="1">35.6</td><td align="left" colspan="1" rowspan="1">36.3</td><td align="left" colspan="1" rowspan="1">40.6</td><td align="left" colspan="1" rowspan="1">33.1</td><td align="left" colspan="1" rowspan="1">29.6</td><td align="left" colspan="1" rowspan="1">33.3</td><td align="left" colspan="1" rowspan="1">37.6</td><td align="left" colspan="1" rowspan="1">35.2</td><td align="left" colspan="1" rowspan="1">32.4</td><td align="left" colspan="1" rowspan="1">30.1</td><td align="left" colspan="1" rowspan="1">32.6</td><td char="." align="char" colspan="1" rowspan="1">0.20</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;West</td><td align="left" colspan="1" rowspan="1">21.5</td><td align="left" colspan="1" rowspan="1">21.8</td><td align="left" colspan="1" rowspan="1">22.3</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">29.2</td><td align="left" colspan="1" rowspan="1">27.4</td><td align="left" colspan="1" rowspan="1">25.3</td><td align="left" colspan="1" rowspan="1">24.4</td><td align="left" colspan="1" rowspan="1">29.8</td><td align="left" colspan="1" rowspan="1">24.5</td><td align="left" colspan="1" rowspan="1">22.4</td><td char="." align="char" colspan="1" rowspan="1">0.23</td></tr><tr><td align="left" colspan="13" rowspan="1">Racial identity (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;White</td><td align="left" colspan="1" rowspan="1">68.4</td><td align="left" colspan="1" rowspan="1">63.4</td><td align="left" colspan="1" rowspan="1">61.2</td><td align="left" colspan="1" rowspan="1">54.7</td><td align="left" colspan="1" rowspan="1">59.8</td><td align="left" colspan="1" rowspan="1">54.8</td><td align="left" colspan="1" rowspan="1">53.5</td><td align="left" colspan="1" rowspan="1">53.5</td><td align="left" colspan="1" rowspan="1">49.6</td><td align="left" colspan="1" rowspan="1">52.9</td><td align="left" colspan="1" rowspan="1">53.5</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;African American</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">17.1</td><td align="left" colspan="1" rowspan="1">15.9</td><td align="left" colspan="1" rowspan="1">18.5</td><td align="left" colspan="1" rowspan="1">11.4</td><td align="left" colspan="1" rowspan="1">16.3</td><td align="left" colspan="1" rowspan="1">17.6</td><td align="left" colspan="1" rowspan="1">17.9</td><td align="left" colspan="1" rowspan="1">19.5</td><td align="left" colspan="1" rowspan="1">18.9</td><td align="left" colspan="1" rowspan="1">15.9</td><td char="." align="char" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hispanic</td><td align="left" colspan="1" rowspan="1">11.3</td><td align="left" colspan="1" rowspan="1">10.8</td><td align="left" colspan="1" rowspan="1">14.8</td><td align="left" colspan="1" rowspan="1">16.1</td><td align="left" colspan="1" rowspan="1">15.6</td><td align="left" colspan="1" rowspan="1">21.6</td><td align="left" colspan="1" rowspan="1">19.7</td><td align="left" colspan="1" rowspan="1">16.3</td><td align="left" colspan="1" rowspan="1">16.7</td><td align="left" colspan="1" rowspan="1">15.4</td><td align="left" colspan="1" rowspan="1">17.4</td><td char="." align="char" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asian or Pacific Islander</td><td align="left" colspan="1" rowspan="1">5.9</td><td align="left" colspan="1" rowspan="1">6.2</td><td align="left" colspan="1" rowspan="1">4.1</td><td align="left" colspan="1" rowspan="1">6.3</td><td align="left" colspan="1" rowspan="1">5.7</td><td align="left" colspan="1" rowspan="1">3.9</td><td align="left" colspan="1" rowspan="1">6.3</td><td align="left" colspan="1" rowspan="1">6.9</td><td align="left" colspan="1" rowspan="1">7.5</td><td align="left" colspan="1" rowspan="1">7.6</td><td align="left" colspan="1" rowspan="1">8.3</td><td char="." align="char" colspan="1" rowspan="1">0.18</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Native American</td><td align="left" colspan="1" rowspan="1">1.4</td><td align="left" colspan="1" rowspan="1">2.3</td><td align="left" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">2.6</td><td align="left" colspan="1" rowspan="1">4.9</td><td align="left" colspan="1" rowspan="1">2.5</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">2.1</td><td align="left" colspan="1" rowspan="1">2.3</td><td char="." align="char" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple races reported</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">1.7</td><td align="left" colspan="1" rowspan="1">2.4</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">5.1</td><td align="left" colspan="1" rowspan="1">3.1</td><td align="left" colspan="1" rowspan="1">2.3</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="13" rowspan="1">Family income (relative to poverty line)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Poor/negative (&#8804;&#8201;poverty line)</td><td align="left" colspan="1" rowspan="1">17.5</td><td align="left" colspan="1" rowspan="1">17.9</td><td align="left" colspan="1" rowspan="1">20.4</td><td align="left" colspan="1" rowspan="1">16.1</td><td align="left" colspan="1" rowspan="1">19.3</td><td align="left" colspan="1" rowspan="1">23.5</td><td align="left" colspan="1" rowspan="1">18.2</td><td align="left" colspan="1" rowspan="1">23.7</td><td align="left" colspan="1" rowspan="1">23.6</td><td align="left" colspan="1" rowspan="1">23.9</td><td align="left" colspan="1" rowspan="1">15.9</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Near poor (up to 125% of the poverty line)</td><td align="left" colspan="1" rowspan="1">7.7</td><td align="left" colspan="1" rowspan="1">6.8</td><td align="left" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">11.5</td><td align="left" colspan="1" rowspan="1">10.1</td><td align="left" colspan="1" rowspan="1">6.7</td><td align="left" colspan="1" rowspan="1">9.9</td><td align="left" colspan="1" rowspan="1">6.2</td><td align="left" colspan="1" rowspan="1">6.5</td><td align="left" colspan="1" rowspan="1">7.2</td><td align="left" colspan="1" rowspan="1">10.6</td><td char="." align="char" colspan="1" rowspan="1">0.14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Low income (125&#8211;200% of the poverty line)</td><td align="left" colspan="1" rowspan="1">22.5</td><td align="left" colspan="1" rowspan="1">20.5</td><td align="left" colspan="1" rowspan="1">18.2</td><td align="left" colspan="1" rowspan="1">19.9</td><td align="left" colspan="1" rowspan="1">15.3</td><td align="left" colspan="1" rowspan="1">20.2</td><td align="left" colspan="1" rowspan="1">21.8</td><td align="left" colspan="1" rowspan="1">19.7</td><td align="left" colspan="1" rowspan="1">18.7</td><td align="left" colspan="1" rowspan="1">16.4</td><td align="left" colspan="1" rowspan="1">19.1</td><td char="." align="char" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Middle income (200&#8211;400% of the poverty line)</td><td align="left" colspan="1" rowspan="1">27.7</td><td align="left" colspan="1" rowspan="1">31.1</td><td align="left" colspan="1" rowspan="1">27.5</td><td align="left" colspan="1" rowspan="1">31.3</td><td align="left" colspan="1" rowspan="1">27.9</td><td align="left" colspan="1" rowspan="1">25.1</td><td align="left" colspan="1" rowspan="1">24.4</td><td align="left" colspan="1" rowspan="1">21.6</td><td align="left" colspan="1" rowspan="1">23.7</td><td align="left" colspan="1" rowspan="1">23.3</td><td align="left" colspan="1" rowspan="1">22.5</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High income (&gt;&#8201;400% of the poverty line)</td><td align="left" colspan="1" rowspan="1">24.6</td><td align="left" colspan="1" rowspan="1">23.6</td><td align="left" colspan="1" rowspan="1">25.5</td><td align="left" colspan="1" rowspan="1">21.2</td><td align="left" colspan="1" rowspan="1">27.2</td><td align="left" colspan="1" rowspan="1">24.3</td><td align="left" colspan="1" rowspan="1">25.6</td><td align="left" colspan="1" rowspan="1">28.7</td><td align="left" colspan="1" rowspan="1">27.4</td><td align="left" colspan="1" rowspan="1">29.2</td><td align="left" colspan="1" rowspan="1">31.8</td><td char="." align="char" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="13" rowspan="1">Insurance coverage (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Any private insurance</td><td align="left" colspan="1" rowspan="1">43.4</td><td align="left" colspan="1" rowspan="1">48.4</td><td align="left" colspan="1" rowspan="1">46.7</td><td align="left" colspan="1" rowspan="1">44.7</td><td align="left" colspan="1" rowspan="1">48.5</td><td align="left" colspan="1" rowspan="1">41.3</td><td align="left" colspan="1" rowspan="1">40.6</td><td align="left" colspan="1" rowspan="1">45.4</td><td align="left" colspan="1" rowspan="1">45.8</td><td align="left" colspan="1" rowspan="1">43.2</td><td align="left" colspan="1" rowspan="1">40.9</td><td char="." align="char" colspan="1" rowspan="1">0.53</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Public insurance (Medicare/Medicaid)</td><td align="left" colspan="1" rowspan="1">52.1</td><td align="left" colspan="1" rowspan="1">46.7</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">49.1</td><td align="left" colspan="1" rowspan="1">46.4</td><td align="left" colspan="1" rowspan="1">52.6</td><td align="left" colspan="1" rowspan="1">53.1</td><td align="left" colspan="1" rowspan="1">50.4</td><td align="left" colspan="1" rowspan="1">50.4</td><td align="left" colspan="1" rowspan="1">55.7</td><td align="left" colspan="1" rowspan="1">58.3</td><td char="." align="char" colspan="1" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Uninsured</td><td align="left" colspan="1" rowspan="1">4.6</td><td align="left" colspan="1" rowspan="1">4.8</td><td align="left" colspan="1" rowspan="1">5.2</td><td align="left" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">5.1</td><td align="left" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">6.2</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">0.7</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="13" rowspan="1">Comorbidities (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ASCVD</td><td align="left" colspan="1" rowspan="1">42.1</td><td align="left" colspan="1" rowspan="1">58.5</td><td align="left" colspan="1" rowspan="1">50.3</td><td align="left" colspan="1" rowspan="1">50.1</td><td align="left" colspan="1" rowspan="1">59.6</td><td align="left" colspan="1" rowspan="1">53.6</td><td align="left" colspan="1" rowspan="1">54.6</td><td align="left" colspan="1" rowspan="1">54.9</td><td align="left" colspan="1" rowspan="1">54.8</td><td align="left" colspan="1" rowspan="1">50.5</td><td align="left" colspan="1" rowspan="1">50.8</td><td char="." align="char" colspan="1" rowspan="1">0.27</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heart failure</td><td align="left" colspan="1" rowspan="1">4.4</td><td align="left" colspan="1" rowspan="1">6.2</td><td align="left" colspan="1" rowspan="1">7.8</td><td align="left" colspan="1" rowspan="1">4.4</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">2.7</td><td align="left" colspan="1" rowspan="1">4.7</td><td align="left" colspan="1" rowspan="1">5.8</td><td align="left" colspan="1" rowspan="1">4.6</td><td align="left" colspan="1" rowspan="1">4.9</td><td align="left" colspan="1" rowspan="1">3.5</td><td char="." align="char" colspan="1" rowspan="1">0.65</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">27.7</td><td align="left" colspan="1" rowspan="1">31.8</td><td align="left" colspan="1" rowspan="1">38.9</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">41.5</td><td align="left" colspan="1" rowspan="1">45.1</td><td align="left" colspan="1" rowspan="1">44.9</td><td align="left" colspan="1" rowspan="1">41.4</td><td align="left" colspan="1" rowspan="1">40.9</td><td align="left" colspan="1" rowspan="1">44.2</td><td align="left" colspan="1" rowspan="1">46.5</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">28.4</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">62.2</td><td align="left" colspan="1" rowspan="1">81.1</td><td align="left" colspan="1" rowspan="1">82.2</td><td align="left" colspan="1" rowspan="1">77.7</td><td align="left" colspan="1" rowspan="1">73.3</td><td align="left" colspan="1" rowspan="1">80.5</td><td align="left" colspan="1" rowspan="1">77.7</td><td align="left" colspan="1" rowspan="1">75.9</td><td align="left" colspan="1" rowspan="1">73.9</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Total expenditure (USD, millions)</td><td align="left" colspan="1" rowspan="1">3.73</td><td align="left" colspan="1" rowspan="1">4.82</td><td align="left" colspan="1" rowspan="1">8.74</td><td align="left" colspan="1" rowspan="1">4.46</td><td align="left" colspan="1" rowspan="1">6.06</td><td align="left" colspan="1" rowspan="1">5.54</td><td align="left" colspan="1" rowspan="1">6.80</td><td align="left" colspan="1" rowspan="1">6.29</td><td align="left" colspan="1" rowspan="1">7.31</td><td align="left" colspan="1" rowspan="1">6.24</td><td align="left" colspan="1" rowspan="1">6.17</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Total out-of-pocket (OOP) expenditure (USD, millions)</td><td align="left" colspan="1" rowspan="1">2.10</td><td align="left" colspan="1" rowspan="1">2.91</td><td align="left" colspan="1" rowspan="1">2.37</td><td align="left" colspan="1" rowspan="1">2.71</td><td align="left" colspan="1" rowspan="1">2.45</td><td align="left" colspan="1" rowspan="1">2.69</td><td align="left" colspan="1" rowspan="1">3.21</td><td align="left" colspan="1" rowspan="1">2.72</td><td align="left" colspan="1" rowspan="1">2.76</td><td align="left" colspan="1" rowspan="1">2.89</td><td align="left" colspan="1" rowspan="1">2.71</td><td char="." align="char" colspan="1" rowspan="1">0.82</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ASA</italic> aspirin, <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease, <italic toggle="yes">USD</italic> United States dollars</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Trend in Aspirin Use</title><p id="Par12">There has been an uptrend in overall ASA use in adults&#8201;&gt;&#8201;40&#160;years and a proportion of ASA use in subgroups with or without ASCVD (<italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The proportion of ASA use in established patients with ASCVD peaked between 2012 and 2015 and has plateaued since, while ASA use for patients without ASCVD continued to increase steadily through the study period. From 2000 to 2021, the low-dose (81&#160;mg) ASA use increased significantly, while the high-dose (325&#160;mg) ASA use decreased (both <italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S2</xref>). In the ASCVD cohort,&#8201;&#8805;&#8201;70-year-old patients were the most prevalent age group with &gt;&#8201;50% using ASA, followed by 50&#8211;69&#160;years and 40&#8211;49&#160;years age groups (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S3</xref>). ASA use in patients with ASCVD&#8201;&#8805;&#8201;70&#160;years decreased after 2008&#8211;09 (<italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01). Among patients without ASCVD using ASA, the age group&#160;50&#8211;69&#160;years was the most prevalent, which showed an overall increasing trend throughout the study period (<italic toggle="yes">p</italic>&#160;trend&#8201;&lt;&#8201;0.01). A significant proportion of patients&#8201;&#8805;&#8201;70&#160;years without a known history of ASCVD continued using ASA throughout the study period, but there appeared to be a downward trend from 2006 to 2007 (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S4</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Trends in aspirin use categorized by atherosclerotic cardiovascular disease status (ASCVD), Medical Expenditure Panel Survey 2000&#8211;2021. <italic toggle="yes">ASA</italic> aspirin, <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40119_2024_385_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Trends in total, low-dose (81&#160;mg), and high-dose (325&#160;mg) aspirin use, Medical Expenditure Panel Survey 2000&#8211;2021. <italic toggle="yes">ASA</italic> aspirin</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40119_2024_385_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Trend of ASA use in patients with (<bold>a</bold>) and without (<bold>b</bold>) ASCVD categorized by age groups, Medical Expenditure Panel Survey 2000&#8211;2021. <italic toggle="yes">ASA</italic> aspirin, <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40119_2024_385_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Expenditure Analysis</title><p id="Par13">The average annual total expenditure on ASA was approximately 60&#160;million US dollars (USD). Out-of-pocket (OOP) expenditures averaged 27.3&#160;million USD per year. Both total and OOP expenditures showed an upward trend, reflecting the growing use and cost of ASA therapy in the USA (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> and Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Trends in total and out-of-pocket ASA expenditure in US dollars, Medical Expenditure Panel Survey 2000&#8211;2021. <italic toggle="yes">ASA</italic> aspirin, <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease, <italic toggle="yes">OOP</italic> out-of-pocket, <italic toggle="yes">USD</italic> United States dollars</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="40119_2024_385_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Predictors of Aspirin Use</title><p id="Par14">While evaluating the predictors of ASA use, we found that female patients had lower odds of ASA use in both cohorts of with and without ASCVD than male patients. Furthermore, residents of Northeastern and Western states had higher odds of using ASA than patients from Southern states. Patients belonging to African American, Hispanic, and Asian/Pacific Islander ethnicity had higher odds of using ASA compared to the White patient population. Among comorbidities, hypertension, diabetes, and dyslipidemia were associated with significantly higher odds of ASA use in both cohorts (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Predictors of aspirin use among adults&#8201;&gt;&#8201;40&#160;years with and without ASCVD, Medical Expenditure Panel Survey, 2000&#8211;2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Demographic characteristics</th><th align="left" colspan="3" rowspan="1">Patients with ASCVD</th><th align="left" colspan="3" rowspan="1">Patients without ASCVD</th></tr><tr><th align="left" colspan="1" rowspan="1">aOR</th><th align="left" colspan="1" rowspan="1">95%&#160;CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>&#160;value</th><th align="left" colspan="1" rowspan="1">aOR</th><th align="left" colspan="1" rowspan="1">95%&#160;CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>&#160;value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td char="." align="char" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">0.99&#8211;1.01</td><td char="." align="char" colspan="1" rowspan="1">0.15</td><td char="." align="char" colspan="1" rowspan="1">1.02</td><td align="left" colspan="1" rowspan="1">1.02&#8211;1.03</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="7" rowspan="1">Age categories</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;40&#8211;49&#160;years</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="3" rowspan="1">1.00 (reference)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;50&#8211;69&#160;years</td><td char="." align="char" colspan="1" rowspan="1">1.16</td><td align="left" colspan="1" rowspan="1">0.90&#8211;1.49</td><td char="." align="char" colspan="1" rowspan="1">0.24</td><td char="." align="char" colspan="1" rowspan="1">1.43</td><td align="left" colspan="1" rowspan="1">1.12&#8211;1.84</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;70&#160;years</td><td char="." align="char" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">0.68&#8211;1.48</td><td char="." align="char" colspan="1" rowspan="1">0.96</td><td char="." align="char" colspan="1" rowspan="1">1.10</td><td align="left" colspan="1" rowspan="1">0.71&#8211;1.68</td><td char="." align="char" colspan="1" rowspan="1">0.67</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="3" rowspan="1">1.00 (reference)</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td char="." align="char" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.71&#8211;0.90</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">0.61&#8211;0.76</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="7" rowspan="1">Regions</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;South</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="3" rowspan="1">1.00 (reference)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Northeast</td><td char="." align="char" colspan="1" rowspan="1">1.31</td><td align="left" colspan="1" rowspan="1">1.10&#8211;1.58</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.54</td><td align="left" colspan="1" rowspan="1">1.24&#8211;1.91</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Midwest</td><td char="." align="char" colspan="1" rowspan="1">1.05</td><td align="left" colspan="1" rowspan="1">0.88&#8211;1.26</td><td char="." align="char" colspan="1" rowspan="1">0.55</td><td char="." align="char" colspan="1" rowspan="1">1.38</td><td align="left" colspan="1" rowspan="1">1.10&#8211;1.75</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;West</td><td char="." align="char" colspan="1" rowspan="1">1.43</td><td align="left" colspan="1" rowspan="1">1.18&#8211;1.75</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.48</td><td align="left" colspan="1" rowspan="1">1.17&#8211;1.86</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="7" rowspan="1">Racial identity</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;White</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="3" rowspan="1">1.00 (reference)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;African American</td><td char="." align="char" colspan="1" rowspan="1">1.88</td><td align="left" colspan="1" rowspan="1">1.62&#8211;2.18</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.98</td><td align="left" colspan="1" rowspan="1">1.69&#8211;2.33</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hispanic</td><td char="." align="char" colspan="1" rowspan="1">2.09</td><td align="left" colspan="1" rowspan="1">1.78&#8211;2.46</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">2.53</td><td align="left" colspan="1" rowspan="1">2.13&#8211;3.00</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asian or Pacific Islander</td><td char="." align="char" colspan="1" rowspan="1">2.23</td><td align="left" colspan="1" rowspan="1">1.70&#8211;2.92</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">2.23</td><td align="left" colspan="1" rowspan="1">1.74&#8211;2.85</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Native American</td><td char="." align="char" colspan="1" rowspan="1">2.71</td><td align="left" colspan="1" rowspan="1">1.48&#8211;4.97</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">6.10</td><td align="left" colspan="1" rowspan="1">3.26&#8211;11.30</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="7" rowspan="1">Family income (relative to Federal Poverty Line)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High income (&gt;&#8201;400% of the poverty line)</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Poor/negative (&#8804;&#8201;100% poverty line)</td><td char="." align="char" colspan="1" rowspan="1">1.62</td><td align="left" colspan="1" rowspan="1">1.34&#8211;1.97</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.99</td><td align="left" colspan="1" rowspan="1">1.66&#8211;2.38</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Near poor (up to 125% of the poverty line)</td><td char="." align="char" colspan="1" rowspan="1">1.29</td><td align="left" colspan="1" rowspan="1">1.10&#8211;1.61</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">1.61</td><td align="left" colspan="1" rowspan="1">1.26&#8211;2.05</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Low income (125&#8211;200% of the poverty line)</td><td char="." align="char" colspan="1" rowspan="1">1.32</td><td align="left" colspan="1" rowspan="1">1.10&#8211;1.62</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.44</td><td align="left" colspan="1" rowspan="1">1.20&#8211;1.73</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Middle income (200&#8211;400% of the poverty line)</td><td char="." align="char" colspan="1" rowspan="1">1.11</td><td align="left" colspan="1" rowspan="1">0.93&#8211;1.31</td><td char="." align="char" colspan="1" rowspan="1">0.22</td><td char="." align="char" colspan="1" rowspan="1">1.12</td><td align="left" colspan="1" rowspan="1">0.96&#8211;1.32</td><td char="." align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="7" rowspan="1">Insurance coverage</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Any private insurance</td><td char="." align="char" colspan="3" rowspan="1">1.00 (reference)</td><td align="left" colspan="3" rowspan="1">1.00 (reference)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Public insurance (Medicare/Medicaid)</td><td char="." align="char" colspan="1" rowspan="1">1.30</td><td align="left" colspan="1" rowspan="1">1.14&#8211;1.48</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.85</td><td align="left" colspan="1" rowspan="1">1.61&#8211;2.13</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Uninsured</td><td char="." align="char" colspan="1" rowspan="1">0.92</td><td align="left" colspan="1" rowspan="1">0.68&#8211;1.21</td><td char="." align="char" colspan="1" rowspan="1">0.51</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.67&#8211;1.16</td><td char="." align="char" colspan="1" rowspan="1">0.38</td></tr><tr><td align="left" colspan="7" rowspan="1">Comorbidities</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hypertension</td><td char="." align="char" colspan="1" rowspan="1">1.39</td><td align="left" colspan="1" rowspan="1">1.16&#8211;1.68</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">2.85</td><td align="left" colspan="1" rowspan="1">2.44&#8211;3.32</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heart failure</td><td char="." align="char" colspan="1" rowspan="1">1.05</td><td align="left" colspan="1" rowspan="1">0.82&#8211;1.35</td><td char="." align="char" colspan="1" rowspan="1">0.66</td><td char="." align="char" colspan="1" rowspan="1">1.48</td><td align="left" colspan="1" rowspan="1">1.10&#8211;1.62</td><td char="." align="char" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Diabetes mellitus</td><td char="." align="char" colspan="1" rowspan="1">1.26</td><td align="left" colspan="1" rowspan="1">1.11&#8211;1.43</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">2.26</td><td align="left" colspan="1" rowspan="1">2.00&#8211;2.56</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hyperlipidemia</td><td char="." align="char" colspan="1" rowspan="1">1.35</td><td align="left" colspan="1" rowspan="1">1.18&#8211;1.54</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td char="." align="char" colspan="1" rowspan="1">1.90</td><td align="left" colspan="1" rowspan="1">1.68&#8211;2.16</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ASA</italic> aspirin, <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease, <italic toggle="yes">aOR</italic> adjusted odds ratio, <italic toggle="yes">CI</italic> confidence interval</p></table-wrap-foot></table-wrap><fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Forest plot depicting the predictors of aspirin use among patients with (<bold>a</bold>) and without (<bold>b</bold>) ASCVD, Medical Expenditure Panel Survey 2000&#8211;2021. <italic toggle="yes">ASCVD</italic> atherosclerotic cardiovascular disease, <italic toggle="yes">FPL</italic> Federal Poverty Line, <italic toggle="yes">Ref.</italic> reference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="40119_2024_385_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p id="Par15">Our study highlights significant trends in the use of ASA among US adults over the past two decades, revealing both positive and concerning patterns in its utilization. First, there was an increase in overall ASA use and its expenditure along with the subsets of patients with and without ASCVD. Second, low-dose ASA use increased, while high-dose ASA has steadily declined over the past two decades. Third, the prevalence of ASA use has increased among women, and minority racial and ethnic groups. Last, a significant proportion of patients aged&#8201;&#8805;&#8201;70&#160;years continue to use ASA in both the with and without ASCVD cohorts.</p><p id="Par16">The overall uptrend in ASA use is likely multifactorial, with possible reasons including the increased awareness regarding ASA use for primary and secondary prevention of cardiovascular diseases. Recommendations by multiple professional societies favored ASA use until data from recent randomized control trials (RCTs) demonstrated a higher risk of bleeding. In 2002, the USPSTF recommended that clinicians consider ASA use for primary prevention in certain patients at increased risk of cardiovascular disease [<xref ref-type="bibr" rid="CR14">14</xref>]. Later, an update released by USPSTF in 2009 consolidated ASA use in men aged 45&#8211;79 and women aged 55&#8211;79 at high risk for ASCVD [<xref ref-type="bibr" rid="CR15">15</xref>]. The 2016 iteration of the guidelines from USPSTF recommended ASA use for primary prevention in those in the 50- to 59-year-old group and 60- to 69-year-old group with elevated cardiovascular risk [<xref ref-type="bibr" rid="CR16">16</xref>]. In 2022, the US Preventive Services Task Force recommended considering low-dose ASA for primary prevention of cardiovascular disease in adults aged 40&#8211;59&#160;years with high risk, but advises against it for those aged 60&#160;years or older [<xref ref-type="bibr" rid="CR7">7</xref>]. Similarly, the Joint Task Forces of the European Society of Cardiology over the years have suggested ASA use for primary prevention in those at an elevated risk [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. However, the ACC/AHA only published guidelines for secondary prevention of ASCVD in 2001 and 2002, emphasizing the importance of secondary preventative interventions, including pharmacological therapy with antiplatelets [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. We noticed a significant increase in ASA use for ASCVD after the study period&#160;2012&#8211;2013. This inflection point noted in 2012&#8211;2013 was likely due to the increased use of ASA for both primary and secondary prevention. The Centers for Medicare &amp; Medicaid Services implemented the Hospital Readmissions Reduction Program to reduce readmissions with certain medical conditions or procedures, including acute myocardial infarction [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, the overall care of patients with AMI has improved over the years, even for metrics not part of quality initiatives. Data from the NCDR&#8211;Acute Coronary Treatment and Intervention Outcomes Network Registry&#8211;Get With The Guidelines registry show that the proportion of patients receiving defect-free care for acute MI significantly increased from 66.0% in 2010 to 77.1% in 2017 [<xref ref-type="bibr" rid="CR22">22</xref>]. The temporal change in the population dynamics could be another contributing factor, as improved survival of patients with ASCVD due to advancement in cardiovascular intervention has created a larger population of older adults eligible for secondary prevention over time. The increased ASA use corresponded with changes in overall expenditure related to ASA during the study period from 2012 to 2017.</p><p id="Par17">The shift toward low-dose ASA use is likely multifactorial and has been reported in prior studies [<xref ref-type="bibr" rid="CR11">11</xref>]. Observational studies have suggested that low-dose ASA is equally efficacious for primary and secondary ASCVD prevention, and clinical trials have failed to show the superiority of one approach over the other [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Following this, the European guidelines only recommend low-dose ASA for secondary prevention [<xref ref-type="bibr" rid="CR5">5</xref>]. We observed an uptrend in the use of ASA among female patients and African Americans and, interestingly, a decline among White patients. Current literature suggests that African Americans and women are more likely to receive suboptimal CVD prevention than other groups [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Our study showed that female patients had lower odds of using ASA for both with and without ASCVD, similar to previously reported findings by Boakye et al. [<xref ref-type="bibr" rid="CR27">27</xref>]. Such disparities can be attributed to poor awareness, lower utilization of healthcare services, and societal barriers [<xref ref-type="bibr" rid="CR28">28</xref>]. Although it is not possible to discern the appropriateness of ASA use in our study, a cross-sectional study by Luepker et al. showed that inappropriate ASA use was noted in at least one in four adults in the upper midwestern area using ASA without an appropriate indication [<xref ref-type="bibr" rid="CR29">29</xref>]. Interestingly, overuse was more common among women in this study. In another study by Bazargan et al. that studied the use of ASA among African Americans, 60% of study participants self-prescribed the medication [<xref ref-type="bibr" rid="CR30">30</xref>]. As such, despite the recommendations for the nonuse of ASA for primary prevention by multiple professional medical societies, an upward trend in its use among populations traditionally known to have suboptimal healthcare utilization is a cause for concern. Future studies should identify the reasons for this increased use of ASA and the appropriateness of ASA use among these groups.</p><p id="Par18">The increasing trend of ASA use in patients without ASCVD is a cause for concern. Our findings are consistent with multiple prior studies that have shown the use of low-dose ASA for primary prevention to be prevalent [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. A study by Boakye et al. reported increased ASA use in the USA from 1998 to 2009, followed by a nonsignificant decline from 2011 to 2019 [<xref ref-type="bibr" rid="CR27">27</xref>]. A study outside of the USA also reported a doubling of ASA use for primary prevention from 2003 to 2017 [<xref ref-type="bibr" rid="CR32">32</xref>]. The findings from studies in the USA contrast with the conclusions of a recent Danish study that reported an overall declining trend in ASA use for primary prevention [<xref ref-type="bibr" rid="CR33">33</xref>]. Low-cost, over-the-counter availability, perceptions about the therapeutic benefit, decreased awareness of bleeding risk, and direct-to-consumer advertising of ASA could be a few factors for such widespread medication use and self-medication by patients [<xref ref-type="bibr" rid="CR34">34</xref>]. Recently, the results of several trials comparing ASA with placebo for primary prevention of ASCVD in patients with diabetes [<xref ref-type="bibr" rid="CR8">8</xref>], patients at moderate cardiovascular disease risk [<xref ref-type="bibr" rid="CR11">11</xref>], and elderly patients [<xref ref-type="bibr" rid="CR9">9</xref>] have shown limited benefit of ASA for ischemic events while significantly increasing bleeding risk. As such, the most recent ACC/AHA guidelines gave a weak recommendation (class&#160;IIb) for ASA use for primary prevention among patients aged 40&#8211;70&#160;years while also recommending avoiding routine ASA use among adults over 70&#160;years [<xref ref-type="bibr" rid="CR10">10</xref>]. The European guidelines have also recommended a similarly conservative approach [<xref ref-type="bibr" rid="CR35">35</xref>]. Despite recent evidence of a lack of significant benefit, a study reported that one in four Americans received ASA for primary prevention without an appropriate indication [<xref ref-type="bibr" rid="CR36">36</xref>]. Furthermore, the use of ASA for primary prevention continues to be very common among the&#8201;&gt;&#8201;70 age group, with nearly one in two individuals reporting ASA use [<xref ref-type="bibr" rid="CR37">37</xref>]. However, the downtrend in ASA use in the&#8201;&#8805;&#8201;70-year age group in the patients without ASCVD cohort is reassuring, given the results of recent RCTs and alignment with societal recommendations. The impact of the change in guidelines and recent trials on ASA use for primary prevention in clinical practice will need to be evaluated. This points toward a need for future monitoring of ASA prescription trends, emphasizing provider and patient education on the appropriate and inappropriate use of ASA for primary and secondary prevention.</p><sec id="Sec14"><title>Limitations</title><p id="Par19">The MEPS database is based on patient-reported self-characteristics such as comorbidities and medications. Therefore, we cannot eliminate the possibility of ASCVD being underreported because of recall bias. However, it is worth noting that the Agency of Healthcare Research and Quality duly performs the validation of random samples to ensure that the results are accurate by matching the providers&#8217; data. While one study reported discrepancies in estimations of results based on MEPS data [<xref ref-type="bibr" rid="CR38">38</xref>], other studies have addressed the sensitivity and specificity of this matter and reported the overall relative accuracy of MEPS data [<xref ref-type="bibr" rid="CR39">39</xref>]. It is plausible that our patients without ASCVD cohort likely included patients using ASA for indications other than primary prevention of ASCVD, such as anti-inflammatory/analgesic, colorectal cancer prevention, preeclampsia prevention, and venous thromboembolism primary or secondary prevention (e.g., after hip and knee replacement or patients who were unable to tolerate anticoagulation for secondary prevention). However, these patients are less likely to contribute significantly to the patients without ASCVD cohort, given the short duration of ASA use usually recommended for these conditions [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec15"><title>Clinical Implication and Potential Interventions</title><p id="Par20">Despite updated guidelines advising against routine ASA use for primary prevention in individuals aged&#8201;&#8805;&#8201;70&#160;years, our findings suggest that many older adults continue to use ASA without appropriate indications. The persistent use of ASA in inappropriate populations underscores the need for targeted educational interventions for healthcare providers. These interventions should aim to ensure healthcare providers are well informed about the latest guidelines and evidence, emphasizing the risks and limited benefits of ASA use in older adults without ASCVD. One should encourage discussions between healthcare providers and patients about the potential risks and benefits of ASA therapy, particularly for primary prevention. This approach can help tailor decisions to individual patient profiles and preferences. To address these issues, development and implementation of comprehensive educational campaigns targeting both healthcare providers and patients is suggested. These campaigns should focus on the latest evidence regarding ASA use, highlighting the risks of inappropriate use. In addition, one should integrate decision support tools within electronic health records (EHRs) to provide real-time guidance to healthcare providers on ASA prescribing practices, ensuring adherence to updated guidelines. One should also establish systems for regular monitoring and auditing of ASA prescribing patterns within healthcare institutions. This can help identify and address deviations from recommended practices.</p></sec></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusions</title><p id="Par21">In this nationally representative retrospective cohort study of non-institutionalized US adults, the use of low-dose ASA increased, and high-dose ASA decreased substantially over the past two&#160;decades along with an increase in its total and out-of-pocket expenditure. We noted that ASA use in patients without ASCVD&#8201;&#8805;&#8201;70&#160;years remains high, and this needs to be more aggressively targeted by healthcare practitioners. Further studies are required to monitor future ASA trends, focusing on effective strategies for educating healthcare professionals and patients on the appropriate low-dose ASA use for primary prevention.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40119_2024_385_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 133 KB)</p></caption></media></supplementary-material></p></sec></body><back><notes notes-type="author-contribution"><title>Author Contribution</title><p>Harshith Thyagaturu: conceptualization, data curation, formal analysis, supervision. Shafaqat Ali: writing&#8212;original draft, writing-review and editing. Karthik Seetharam: writing&#8212;original draft, resources. Prakash Upreti: resources, writing&#8212;review and editing. Akshith Doddi: writing&#8212;original draft. Lalitsiri Atti: validation, data curation. Nicholas Roma: writing-review and editing. Jordan L. Lacoste: conceptualization, project administration. Aakash Angirekula: visualization, validation. Joseph Salami: methodology. Khurram Nasir: methodology, project administration, writing&#8212;review and editing. Sudarshan Balla: conceptualization, methodology, writing&#8212;review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data used in this study is publicly available from the MEPS database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data_files.jsp">https://meps.ahrq.gov/data_stats/download_data_files.jsp</ext-link>).</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par22">Harshith Thyagaturu, Shafaqat Ali, Karthik Seetharam, Prakash Upreti, Akshith Doddi, Lalitsiri Atti, Nicholas Roma, Jordan L. Lacoste, Aakash Angirekula, Joseph Salami, Khurram Nasir, and Sudarshan Balla have nothing to disclose. Karthik Seetharam is an Editorial Board member of <italic toggle="yes">Cardiology and Therapy</italic>. Karthik Seetharam was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par23">This study used publicly available de-identified data from the MEPS website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data_files.jsp">https://meps.ahrq.gov/data_stats/download_data_files.jsp</ext-link>). Hence, ethical approval was not obtained.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virani</surname><given-names>SS</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2021 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2021</year><volume>143</volume><issue>8</issue><fpage>e254</fpage><lpage>e743</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000950</pub-id><pub-id pub-id-type="pmid">33501848</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254&#8211;743. 10.1161/CIR.0000000000000950.<pub-id pub-id-type="pmid">33501848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>NB</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>LD</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name><etal/></person-group><article-title>CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors&#8212;United States, 2005&#8211;2013</article-title><source>MMWR Suppl</source><year>2014</year><volume>63</volume><issue>4</issue><fpage>3</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">25356673</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Johnson NB, Hayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors&#8212;United States, 2005&#8211;2013. MMWR Suppl. 2014;63(4):3&#8211;27.<pub-id pub-id-type="pmid">25356673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chobufo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Singla</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>EU</given-names></name><name name-style="western"><surname>Michos</surname><given-names>ED</given-names></name><name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></name><name name-style="western"><surname>Balla</surname><given-names>S</given-names></name></person-group><article-title>Temporal trends in atherosclerotic cardiovascular disease risk among US adults. Analysis of the National Health and Nutrition Examination Survey, 1999&#8211;2018</article-title><source>Eur J Prev Cardiol</source><year>2022</year><volume>29</volume><issue>18</issue><fpage>2289</fpage><lpage>2300</lpage><pub-id pub-id-type="doi">10.1093/eurjpc/zwac161</pub-id><pub-id pub-id-type="pmid">35919951</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chobufo MD, Singla A, Rahman EU, Michos ED, Whelton PK, Balla S. Temporal trends in atherosclerotic cardiovascular disease risk among US adults. Analysis of the National Health and Nutrition Examination Survey, 1999&#8211;2018. Eur J Prev Cardiol. 2022;29(18):2289&#8211;300. 10.1093/eurjpc/zwac161.<pub-id pub-id-type="pmid">35919951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwac161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chobufo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Regner</surname><given-names>SR</given-names></name><name name-style="western"><surname>Zeb</surname><given-names>I</given-names></name><name name-style="western"><surname>Lacoste</surname><given-names>JL</given-names></name><name name-style="western"><surname>Virani</surname><given-names>SS</given-names></name><name name-style="western"><surname>Balla</surname><given-names>S</given-names></name></person-group><article-title>Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017&#8211;2020</article-title><source>Eur J Prev Cardiol</source><year>2022</year><volume>29</volume><issue>14</issue><fpage>1830</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1093/eurjpc/zwac103</pub-id><pub-id pub-id-type="pmid">35653373</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017&#8211;2020. Eur J Prev Cardiol. 2022;29(14):1830&#8211;8. 10.1093/eurjpc/zwac103.<pub-id pub-id-type="pmid">35653373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwac103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knuuti</surname><given-names>J</given-names></name><name name-style="western"><surname>Wijns</surname><given-names>W</given-names></name><name name-style="western"><surname>Saraste</surname><given-names>A</given-names></name><etal/></person-group><article-title>2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>3</issue><fpage>407</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz425</pub-id><pub-id pub-id-type="pmid">31504439</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407&#8211;77. 10.1093/eurheartj/ehz425.<pub-id pub-id-type="pmid">31504439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehz425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>G</given-names></name><etal/></person-group><article-title>2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>25 Suppl 2</issue><fpage>S49</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000437741.48606.98</pub-id><pub-id pub-id-type="pmid">24222018</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. 10.1161/01.cir.0000437741.48606.98.<pub-id pub-id-type="pmid">24222018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.0000437741.48606.98</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Force</surname><given-names>USPST</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>KW</given-names></name><name name-style="western"><surname>Barry</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement</article-title><source>JAMA</source><year>2022</year><volume>327</volume><issue>16</issue><fpage>1577</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.4983</pub-id><pub-id pub-id-type="pmid">35471505</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Force USPST, Davidson KW, Barry MJ, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577&#8211;84. 10.1001/jama.2022.4983.<pub-id pub-id-type="pmid">35471505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.4983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><collab>ASCEND Study Collaborative Group</collab><name name-style="western"><surname>Bowman</surname><given-names>L</given-names></name><name name-style="western"><surname>Mafham</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of aspirin for primary prevention in persons with diabetes mellitus</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>16</issue><fpage>1529</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1804988</pub-id><pub-id pub-id-type="pmid">30146931</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529&#8211;39. 10.1056/NEJMoa1804988.<pub-id pub-id-type="pmid">30146931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1804988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>R</given-names></name><name name-style="western"><surname>Woods</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Effect of aspirin on cardiovascular events and bleeding in the healthy elderly</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>16</issue><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805819</pub-id><pub-id pub-id-type="pmid">30221597</pub-id><pub-id pub-id-type="pmcid">PMC6289056</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509&#8211;18. 10.1056/NEJMoa1805819.<pub-id pub-id-type="pmid">30221597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1805819</pub-id><pub-id pub-id-type="pmcid">PMC6289056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnett</surname><given-names>DK</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>RS</given-names></name><name name-style="western"><surname>Albert</surname><given-names>MA</given-names></name><etal/></person-group><article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title><source>Circulation</source><year>2019</year><volume>140</volume><issue>11</issue><fpage>e596</fpage><lpage>e646</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000678</pub-id><pub-id pub-id-type="pmid">30879355</pub-id><pub-id pub-id-type="pmcid">PMC7734661</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596&#8211;646. 10.1161/CIR.0000000000000678.<pub-id pub-id-type="pmid">30879355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000678</pub-id><pub-id pub-id-type="pmcid">PMC7734661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brotons</surname><given-names>C</given-names></name><name name-style="western"><surname>Coppolecchia</surname><given-names>R</given-names></name><etal/></person-group><article-title>Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume><issue>10152</issue><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31924-X</pub-id><pub-id pub-id-type="pmid">30158069</pub-id><pub-id pub-id-type="pmcid">PMC7255888</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036&#8211;46. 10.1016/S0140-6736(18)31924-X.<pub-id pub-id-type="pmid">30158069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31924-X</pub-id><pub-id pub-id-type="pmcid">PMC7255888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>HM</given-names></name><name name-style="western"><surname>de Lemos</surname><given-names>JA</given-names></name><name name-style="western"><surname>Enriquez</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR)</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2014</year><volume>7</volume><issue>5</issue><fpage>701</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000822</pub-id><pub-id pub-id-type="pmid">25116897</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;7(5):701&#8211;7. 10.1161/CIRCOUTCOMES.113.000822.<pub-id pub-id-type="pmid">25116897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCOUTCOMES.113.000822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Medical Expenditure Panel Survey. An official website of the Department of Health &amp; Human Services. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://meps.ahrq.gov/mepsweb/">https://meps.ahrq.gov/mepsweb/</ext-link>. Accessed 25 Feb 2024.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Force</surname><given-names>USPST</given-names></name></person-group><article-title>Aspirin for the primary prevention of cardiovascular events: recommendation and rationale</article-title><source>Ann Intern Med</source><year>2002</year><volume>136</volume><issue>2</issue><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-136-2-200201150-00015</pub-id><pub-id pub-id-type="pmid">11790071</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Force USPST. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136(2):157&#8211;60. 10.7326/0003-4819-136-2-200201150-00015.<pub-id pub-id-type="pmid">11790071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-136-2-200201150-00015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><collab>US Preventive Services Task Force</collab></person-group><article-title>Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><issue>6</issue><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-150-6-200903170-00008</pub-id><pub-id pub-id-type="pmid">19293072</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396&#8211;404. 10.7326/0003-4819-150-6-200903170-00008.<pub-id pub-id-type="pmid">19293072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-150-6-200903170-00008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bibbins-Domingo</surname><given-names>K</given-names></name><collab>US Preventive Services Task Force</collab></person-group><article-title>Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force Recommendation Statement</article-title><source>Ann Intern Med</source><year>2016</year><volume>164</volume><issue>12</issue><fpage>836</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.7326/M16-0577</pub-id><pub-id pub-id-type="pmid">27064677</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Bibbins-Domingo K, US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836&#8211;45. 10.7326/M16-0577.<pub-id pub-id-type="pmid">27064677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M16-0577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>I</given-names></name><name name-style="western"><surname>Atar</surname><given-names>D</given-names></name><name name-style="western"><surname>Borch-Johnsen</surname><given-names>K</given-names></name><etal/></person-group><article-title>European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2007</year><volume>14</volume><issue>Suppl 2</issue><fpage>E1</fpage><lpage>E40</lpage><pub-id pub-id-type="doi">10.1097/01.hjr.0000277984.31558.c4</pub-id><pub-id pub-id-type="pmid">17726406</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1&#8211;40. 10.1097/01.hjr.0000277984.31558.c4.<pub-id pub-id-type="pmid">17726406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.hjr.0000277984.31558.c4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perk</surname><given-names>J</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>G</given-names></name><name name-style="western"><surname>Gohlke</surname><given-names>H</given-names></name><etal/></person-group><article-title>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>13</issue><fpage>1635</fpage><lpage>1701</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs092</pub-id><pub-id pub-id-type="pmid">22555213</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635&#8211;701. 10.1093/eurheartj/ehs092.<pub-id pub-id-type="pmid">22555213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehs092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Blair</surname><given-names>SN</given-names></name><name name-style="western"><surname>Bonow</surname><given-names>RO</given-names></name><etal/></person-group><article-title>AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><issue>5</issue><fpage>1581</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(01)01682-5</pub-id><pub-id pub-id-type="pmid">11691544</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38(5):1581&#8211;3. 10.1016/s0735-1097(01)01682-5.<pub-id pub-id-type="pmid">11691544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0735-1097(01)01682-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleg</surname><given-names>JL</given-names></name><name name-style="western"><surname>Forman</surname><given-names>DE</given-names></name><name name-style="western"><surname>Berra</surname><given-names>K</given-names></name><etal/></person-group><article-title>Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2013</year><volume>128</volume><issue>22</issue><fpage>2422</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000436752.99896.22</pub-id><pub-id pub-id-type="pmid">24166575</pub-id><pub-id pub-id-type="pmcid">PMC4171129</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128(22):2422&#8211;46. 10.1161/01.cir.0000436752.99896.22.<pub-id pub-id-type="pmid">24166575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.0000436752.99896.22</pub-id><pub-id pub-id-type="pmcid">PMC4171129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Centers for Medicare &amp; Medicaid Services, Hospital Readmissions Reduction Program (HRRP). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program</ext-link>. Accessed 25 July 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202208-1551ED</pub-id><pub-id pub-id-type="pmcid">PMC9952858</pub-id><pub-id pub-id-type="pmid">36018579</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>NR</given-names></name><name name-style="western"><surname>Udell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2019</year><volume>12</volume><issue>3</issue><fpage>e004983</fpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.118.004983</pub-id><pub-id pub-id-type="pmid">30871375</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Desai NR, Udell JA, Wang Y, et al. Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care. Circ Cardiovasc Qual Outcomes. 2019;12(3): e004983. 10.1161/CIRCOUTCOMES.118.004983.<pub-id pub-id-type="pmid">30871375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCOUTCOMES.118.004983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>WS</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>H</given-names></name><name name-style="western"><surname>Wruck</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Comparative effectiveness of aspirin dosing in cardiovascular disease</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>21</issue><fpage>1981</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2102137</pub-id><pub-id pub-id-type="pmid">33999548</pub-id><pub-id pub-id-type="pmcid">PMC9908069</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981&#8211;90. 10.1056/NEJMoa2102137.<pub-id pub-id-type="pmid">33999548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102137</pub-id><pub-id pub-id-type="pmcid">PMC9908069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><collab>Antithrombotic Trialists' Collaboration</collab></person-group><article-title>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</article-title><source>BMJ</source><year>2002</year><volume>324</volume><issue>7329</issue><fpage>71</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1136/bmj.324.7329.71</pub-id><pub-id pub-id-type="pmid">11786451</pub-id><pub-id pub-id-type="pmcid">PMC64503</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71&#8211;86. 10.1136/bmj.324.7329.71.<pub-id pub-id-type="pmid">11786451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.324.7329.71</pub-id><pub-id pub-id-type="pmcid">PMC64503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ansa</surname><given-names>BE</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Aspirin use among adults with cardiovascular disease in the United States: implications for an intervention approach</article-title><source>J Clin Med</source><year>2019</year><pub-id pub-id-type="doi">10.3390/jcm8020264</pub-id><pub-id pub-id-type="pmid">30791560</pub-id><pub-id pub-id-type="pmcid">PMC6406947</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ansa BE, Hoffman Z, Lewis N, et al. Aspirin use among adults with cardiovascular disease in the United States: implications for an intervention approach. J Clin Med. 2019. 10.3390/jcm8020264.<pub-id pub-id-type="pmid">30791560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8020264</pub-id><pub-id pub-id-type="pmcid">PMC6406947</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opotowsky</surname><given-names>AR</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></name></person-group><article-title>Gender differences in aspirin use among adults with coronary heart disease in the United States</article-title><source>J Gen Intern Med</source><year>2007</year><volume>22</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s11606-007-0116-5</pub-id><pub-id pub-id-type="pmid">17351840</pub-id><pub-id pub-id-type="pmcid">PMC1824779</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med. 2007;22(1):55&#8211;61. 10.1007/s11606-007-0116-5.<pub-id pub-id-type="pmid">17351840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-007-0116-5</pub-id><pub-id pub-id-type="pmcid">PMC1824779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boakye</surname><given-names>E</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>SMI</given-names></name><name name-style="western"><surname>Obisesan</surname><given-names>OH</given-names></name><etal/></person-group><article-title>Aspirin for cardiovascular disease prevention among adults in the United States: trends, prevalence, and participant characteristics associated with use</article-title><source>Am J Prev Cardiol</source><year>2021</year><volume>8</volume><fpage>100256</fpage><pub-id pub-id-type="doi">10.1016/j.ajpc.2021.100256</pub-id><pub-id pub-id-type="pmid">34632437</pub-id><pub-id pub-id-type="pmcid">PMC8488247</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Boakye E, Uddin SMI, Obisesan OH, et al. Aspirin for cardiovascular disease prevention among adults in the United States: trends, prevalence, and participant characteristics associated with use. Am J Prev Cardiol. 2021;8:100256. 10.1016/j.ajpc.2021.100256.<pub-id pub-id-type="pmid">34632437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpc.2021.100256</pub-id><pub-id pub-id-type="pmcid">PMC8488247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>M</given-names></name><name name-style="western"><surname>Vaartjes</surname><given-names>I</given-names></name><etal/></person-group><article-title>Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>11</issue><fpage>e014742</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.014742</pub-id><pub-id pub-id-type="pmid">32431190</pub-id><pub-id pub-id-type="pmcid">PMC7429003</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhao M, Woodward M, Vaartjes I, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(11):e014742. 10.1161/JAHA.119.014742.<pub-id pub-id-type="pmid">32431190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.119.014742</pub-id><pub-id pub-id-type="pmcid">PMC7429003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luepker</surname><given-names>RV</given-names></name><name name-style="western"><surname>Oldenburg</surname><given-names>NC</given-names></name><name name-style="western"><surname>Misialek</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Aspirin use and misuse for the primary prevention of cardiovascular diseases</article-title><source>Am J Prev Med</source><year>2021</year><volume>60</volume><issue>4</issue><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2020.10.025</pub-id><pub-id pub-id-type="pmid">33549391</pub-id><pub-id pub-id-type="pmcid">PMC8045673</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Luepker RV, Oldenburg NC, Misialek JR, et al. Aspirin use and misuse for the primary prevention of cardiovascular diseases. Am J Prev Med. 2021;60(4):513&#8211;9. 10.1016/j.amepre.2020.10.025.<pub-id pub-id-type="pmid">33549391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2020.10.025</pub-id><pub-id pub-id-type="pmcid">PMC8045673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazargan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wisseh</surname><given-names>C</given-names></name><name name-style="western"><surname>Adinkrah</surname><given-names>E</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>S</given-names></name><name name-style="western"><surname>King</surname><given-names>EO</given-names></name><name name-style="western"><surname>Assari</surname><given-names>S</given-names></name></person-group><article-title>Low-dose aspirin use among African American older adults</article-title><source>J Am Board Fam Med</source><year>2021</year><volume>34</volume><issue>1</issue><fpage>132</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.3122/jabfm.2021.01.200322</pub-id><pub-id pub-id-type="pmid">33452091</pub-id><pub-id pub-id-type="pmcid">PMC7987229</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bazargan M, Wisseh C, Adinkrah E, Boyce S, King EO, Assari S. Low-dose aspirin use among African American older adults. J Am Board Fam Med. 2021;34(1):132&#8211;43. 10.3122/jabfm.2021.01.200322.<pub-id pub-id-type="pmid">33452091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3122/jabfm.2021.01.200322</pub-id><pub-id pub-id-type="pmcid">PMC7987229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashraf</surname><given-names>M</given-names></name><name name-style="western"><surname>Jan</surname><given-names>MF</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>TK</given-names></name><name name-style="western"><surname>Carnahan</surname><given-names>R</given-names></name><name name-style="western"><surname>Zlochiver</surname><given-names>V</given-names></name><name name-style="western"><surname>Allaqaband</surname><given-names>SQ</given-names></name></person-group><article-title>Sex disparities in diagnostic evaluation and revascularization in patients with acute myocardial infarction&#8212;a 15-year nationwide study</article-title><source>J Am Heart Assoc</source><year>2023</year><volume>12</volume><issue>6</issue><fpage>e027716</fpage><pub-id pub-id-type="doi">10.1161/JAHA.122.027716</pub-id><pub-id pub-id-type="pmid">36926995</pub-id><pub-id pub-id-type="pmcid">PMC10111558</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ashraf M, Jan MF, Bajwa TK, Carnahan R, Zlochiver V, Allaqaband SQ. Sex disparities in diagnostic evaluation and revascularization in patients with acute myocardial infarction&#8212;a 15-year nationwide study. J Am Heart Assoc. 2023;12(6):e027716. 10.1161/JAHA.122.027716.<pub-id pub-id-type="pmid">36926995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.122.027716</pub-id><pub-id pub-id-type="pmcid">PMC10111558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drai</surname><given-names>E</given-names></name><name name-style="western"><surname>Marques-Vidal</surname><given-names>P</given-names></name><name name-style="western"><surname>Bochud</surname><given-names>M</given-names></name><name name-style="western"><surname>Vaucher</surname><given-names>J</given-names></name></person-group><article-title>Temporal trends in low-dose aspirin use (from the CoLaus|PsyCoLaus Study)</article-title><source>Am J Cardiol</source><year>2023</year><volume>190</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2022.11.037</pub-id><pub-id pub-id-type="pmid">36565510</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Drai E, Marques-Vidal P, Bochud M, Vaucher J. Temporal trends in low-dose aspirin use (from the CoLaus|PsyCoLaus Study). Am J Cardiol. 2023;190:61&#8211;6. 10.1016/j.amjcard.2022.11.037.<pub-id pub-id-type="pmid">36565510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2022.11.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>AMD</given-names></name><name name-style="western"><surname>Pareek</surname><given-names>M</given-names></name><name name-style="western"><surname>Kragholm</surname><given-names>KH</given-names></name><name name-style="western"><surname>Torp-Pedersen</surname><given-names>C</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>JW</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>EB</given-names></name></person-group><article-title>Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes</article-title><source>Eur J Prev Cardiol</source><year>2023</year><pub-id pub-id-type="doi">10.1093/eurjpc/zwad092</pub-id><pub-id pub-id-type="pmid">36947152</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kristensen AMD, Pareek M, Kragholm KH, Torp-Pedersen C, McEvoy JW, Prescott EB. Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. Eur J Prev Cardiol. 2023. 10.1093/eurjpc/zwad092.<pub-id pub-id-type="pmid">36947152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwad092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Josefson</surname><given-names>D</given-names></name></person-group><article-title>Bayer made to tone down aspirin advertisements</article-title><source>West J Med</source><year>2000</year><volume>172</volume><issue>3</issue><fpage>154</fpage><pub-id pub-id-type="doi">10.1136/ewjm.172.3.154</pub-id><pub-id pub-id-type="pmid">18751243</pub-id><pub-id pub-id-type="pmcid">PMC1070790</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Josefson D. Bayer made to tone down aspirin advertisements. West J Med. 2000;172(3):154. 10.1136/ewjm.172.3.154.<pub-id pub-id-type="pmid">18751243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ewjm.172.3.154</pub-id><pub-id pub-id-type="pmcid">PMC1070790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piepoli</surname><given-names>MF</given-names></name><name name-style="western"><surname>Hoes</surname><given-names>AW</given-names></name><name name-style="western"><surname>Agewall</surname><given-names>S</given-names></name><etal/></person-group><article-title>2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>29</issue><fpage>2315</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw106</pub-id><pub-id pub-id-type="pmid">27222591</pub-id><pub-id pub-id-type="pmcid">PMC4986030</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315&#8211;81. 10.1093/eurheartj/ehw106.<pub-id pub-id-type="pmid">27222591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehw106</pub-id><pub-id pub-id-type="pmcid">PMC4986030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hira</surname><given-names>RS</given-names></name><name name-style="western"><surname>Gosch</surname><given-names>KL</given-names></name><name name-style="western"><surname>Kazi</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Potential impact of the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease recommendations on the inappropriate routine use of aspirin and aspirin use without a recommended indication for primary prevention of cardiovascular disease in cardiology practices: insights from the NCDR PINNACLE Registry</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2022</year><volume>15</volume><issue>3</issue><fpage>e007979</fpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.121.007979</pub-id><pub-id pub-id-type="pmid">35098732</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hira RS, Gosch KL, Kazi DS, et al. Potential impact of the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease recommendations on the inappropriate routine use of aspirin and aspirin use without a recommended indication for primary prevention of cardiovascular disease in cardiology practices: insights from the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022;15(3): e007979. 10.1161/CIRCOUTCOMES.121.007979.<pub-id pub-id-type="pmid">35098732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCOUTCOMES.121.007979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>TG</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Ross</surname><given-names>JS</given-names></name><name name-style="western"><surname>Coll</surname><given-names>PP</given-names></name></person-group><article-title>Age-related trajectories of cardiovascular risk and use of aspirin and statin among US adults aged 50 or older, 2011&#8211;2018</article-title><source>J Am Geriatr Soc</source><year>2021</year><volume>69</volume><issue>5</issue><fpage>1272</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1111/jgs.17038</pub-id><pub-id pub-id-type="pmid">33598936</pub-id><pub-id pub-id-type="pmcid">PMC9869399</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Rhee TG, Kumar M, Ross JS, Coll PP. Age-related trajectories of cardiovascular risk and use of aspirin and statin among US adults aged 50 or older, 2011&#8211;2018. J Am Geriatr Soc. 2021;69(5):1272&#8211;82. 10.1111/jgs.17038.<pub-id pub-id-type="pmid">33598936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.17038</pub-id><pub-id pub-id-type="pmcid">PMC9869399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>SC</given-names></name><name name-style="western"><surname>Zuvekas</surname><given-names>SH</given-names></name><name name-style="western"><surname>Zodet</surname><given-names>MW</given-names></name></person-group><article-title>Implications of the accuracy of MEPS prescription drug data for health services research</article-title><source>Inquiry Fall</source><year>2011</year><volume>48</volume><issue>3</issue><fpage>242</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.5034/inquiryjrnl_48.03.04</pub-id><pub-id pub-id-type="pmid">22235548</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hill SC, Zuvekas SH, Zodet MW. Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry Fall. 2011;48(3):242&#8211;59. 10.5034/inquiryjrnl_48.03.04.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5034/inquiryjrnl_48.03.04</pub-id><pub-id pub-id-type="pmid">22235548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machlin</surname><given-names>S</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><name name-style="western"><surname>Elixhauser</surname><given-names>A</given-names></name><name name-style="western"><surname>Beauregard</surname><given-names>K</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>C</given-names></name></person-group><article-title>Sensitivity of household reported medical conditions in the medical expenditure panel survey</article-title><source>Med Care</source><year>2009</year><volume>47</volume><issue>6</issue><fpage>618</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1097/MLR.0b013e318195fa79</pub-id><pub-id pub-id-type="pmid">19433993</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Machlin S, Cohen J, Elixhauser A, Beauregard K, Steiner C. Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care. 2009;47(6):618&#8211;25. 10.1097/MLR.0b013e318195fa79.<pub-id pub-id-type="pmid">19433993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0b013e318195fa79</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matharu</surname><given-names>GS</given-names></name><name name-style="western"><surname>Kunutsor</surname><given-names>SK</given-names></name><name name-style="western"><surname>Judge</surname><given-names>A</given-names></name><name name-style="western"><surname>Blom</surname><given-names>AW</given-names></name><name name-style="western"><surname>Whitehouse</surname><given-names>MR</given-names></name></person-group><article-title>Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials</article-title><source>JAMA Intern Med</source><year>2020</year><volume>180</volume><issue>3</issue><fpage>376</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2019.6108</pub-id><pub-id pub-id-type="pmid">32011647</pub-id><pub-id pub-id-type="pmcid">PMC7042877</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2020;180(3):376&#8211;84. 10.1001/jamainternmed.2019.6108.<pub-id pub-id-type="pmid">32011647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2019.6108</pub-id><pub-id pub-id-type="pmcid">PMC7042877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>DR</given-names></name><name name-style="western"><surname>Dunbar</surname><given-names>M</given-names></name><name name-style="western"><surname>Murnaghan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><issue>8</issue><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1712746</pub-id><pub-id pub-id-type="pmid">29466159</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699&#8211;707. 10.1056/NEJMoa1712746.<pub-id pub-id-type="pmid">29466159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1712746</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>